New products will expand existing microbiology offerings and integrate new contamination control strategies ROCKVILLE, Md. , Oct. 21, 2024 /PRNewswire/ -- Today, the U.
S. Pharmacopeia (USP) announced the acquisition of Stratix Labs, a microbiology technology company based in Saint Paul, MN. This acquisition marks a significant milestone for USP's portfolio, as it will expand its microbiological solutions supporting microbial contamination control with broad applications across pharmaceuticals, including biologics and compounded medications.
Microbiological quality control is essential to ensure fundamental contamination control measures are in place during pharmaceutical production and preparation. Increased demand and expedited timelines require the industry to identify and implement new approaches to quality control throughout the drug production process, particularly for sterile products. By acquiring Stratix Labs, USP will be better equipped to help drug manufacturers, developers, and compounding entities address industry gaps in microbial contamination control strategies, mitigating the risk of contaminated products reaching patients.
"This is an exciting moment for USP as we continue to develop and deliver the latest standards and solutions to meet the needs of the industry today and help ensure quality at every stage of development, manufacturing and delivery in pharmaceutical manufacturing and compounding settings," said Fouad Atouf, Ph.D., Senior Vice President, Glob.